February 27, 2020 / 10:28 PM / a month ago

Mylan must face certified EpiPen class action, judge rules

A federal judge on Thursday said plaintiffs suing Mylan NV for engaging in an allegedly unlawful scheme to squelch competition and sharply raise prices for its EpiPen allergy treatment can proceed as a class.

U.S. District Judge Daniel Crabtree in Kansas City, Kansas, certified two classes of EpiPen purchasers to pursue racketeering and state antitrust claims against Mylan and Pfizer Inc, which makes EpiPens for Mylan to market.

To read the full story on WestlawNext Practitioner Insights, click here: bit.ly/32ACbVf

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below